

# Christopher Moore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4623198/publications.pdf>

Version: 2024-02-01

7  
papers

491  
citations

1307594

7  
h-index

1720034

7  
g-index

9  
all docs

9  
docs citations

9  
times ranked

893  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Science Translational Medicine, 2019, 11, .	12.4	150
2	Requirement for Interaction of PI3-Kinase p110 $\alpha$ with RAS in Lung Tumor Maintenance. Cancer Cell, 2013, 24, 617-630.	16.8	148
3	RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. Cancer Cell, 2019, 36, 68-83.e9.	16.8	104
4	Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Nature Communications, 2021, 12, 5906.	12.8	36
5	Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Science Translational Medicine, 2021, 13, .	12.4	19
6	Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN $\alpha$ null triple negative breast cancer. EMBO Molecular Medicine, 2020, 12, e11987.	6.9	17
7	<i>ATMIN</i> Is a Tumor Suppressor Gene in Lung Adenocarcinoma. Cancer Research, 2019, 79, 5159-5166.	0.9	10